Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Heterogeneity of chromatin modifications in testicular spermatocytic seminoma point toward an epigenetically unstable phenotype

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Isolated Ocular Sarcoidosis Mimicking Ring Melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. WHO grade I meningiomas: classification-tree for prognostic factors of survival

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Meningiomas are rare in children. They are highly complex, harboring unique clinical and pathological characteristics, and many occur in patients with neurofibromatosis type 2. Hereby, we present a case of a two-year-old boy presented with a diagnostically challenging intraventricular tumor. It was incompletely resected 6 times over 14 months but kept progressing and was ultimately deemed unresectable. Histologically, the tumor was initially classified as schwannoma, but extensive international review concluded it was most likely an atypical meningioma, WHO grade II. Comprehensive genomic profiling revealed a TFG-ROS1 fusion, suggesting that ROS1-signaling pathway alterations were driving the tumor growth. In light of this new information, the possibility of a diagnosis of inflammatory myofibroblastic tumor was considered; however the histopathological results were not conclusive. This specific molecular finding allowed the potential use of precision medicine and the patient was enrolled in the AcSé phase 2 trial with crizotinib (NCT02034981), leading to a prolonged partial tumor response which is persisting since 14 months. This case highlights the value of precision cancer medicine in children.

Original languageEnglish
JournalCancer genetics
Volume212-213
Pages (from-to)32-37
Number of pages6
ISSN2210-7762
DOIs
Publication statusPublished - Apr 2017

    Research areas

  • Child, Preschool, Diagnosis, Differential, Gene Fusion, Humans, Male, Meningeal Neoplasms, Meningioma, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Pyrazoles, Pyridines, Transforming Growth Factors, Case Reports, Journal Article

ID: 52348038